Colorectal Cancer | Access and Reimbursement | EU5 | 2017
Seven premium-priced therapies—Avastin (Roche), Erbitux (Merck KGaA), Vectibix (Amgen), Zaltrap (Regeneron/Sanofi), Cyramza (Eli Lilly), Stivarga (Bayer HealthCare), and Lonsurf (Servier)—are approved in Europe for metastatic colorectal cancer. Cyramza and Lonsurf are recent additions to the treatment armamentarium, and further options look set to penetrate the market in the next few years. Ever-increasing and ever-more-costly treatment options, as well as the evolution of biomarker-driven prescribing for colorectal cancer, and the costs that go with it, mean oncologists are striving to optimize the treatment algorithm and maximize treatment outcome for patients, while payers are balancing clinical need with economic constraints. This research analyzes the evolving prescribing landscape for metastatic colorectal cancer, and the impact of payer policy upon it.
Questions Answered
- What are the current drivers of and barriers to prescribing of key brands for mCRC, and what are the main cost-related and clinical constraints on uptake?
- How do European product labeling and national, regional, and local reimbursement restrictions differentially impact use of key brands in mCRC?
- How might evolving healthcare reforms and cost-containment strategies affect reimbursement of novel agents? How challenging will country– and region-specific prescribing constraints be for uptake of these therapies?
- To what extent will oncologists and payers embrace the costly emerging agents Keytruda (Merck & Co.), triplet combination binimetinib, encorafenib, and Erbitux (Array BioPharma/Pierre Fabre/Merck KGaA), and Tecentriq plus Cotellic (Roche)?
Product Description
Access & Reimbursement: Provides in-depth insight into the impact of payer policy on physician prescribing behavior so you can build your market access strategy and optimize your brand positioning.
